Exicure's operating expenses in Q4 2024 were not available. However, the company's General and Administrative (G&A) expenses were significantly reduced compared to the previous year. The G&A expense for the year ended December 31, 2024, was $5.4 million, down from $11.7 million in the year ended December 31, 20231. This decrease was due to higher costs in 2023 related to separation pay of former executives and related stock-based compensation expense, payroll and related benefits, legal and consulting fees, facility and lease costs, and depreciation from property and equipment1. Additionally, the Research and Development (R&D) expense for the year ended December 31, 2024, was $0, reflecting the stoppage of clinical, preclinical, and discovery program activities and a reduction in employee headcount1.
5/8/2025 04:37am
